ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
A Microwell Array Embedded Microfluidic Gradient Platform for Drug Screening on Tumor Spheroids.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Microfluidic gradient platforms, especially flow-based types, have emerged as promising tools in 3D tumor spheroid research, as they enable precise control of concentration gradients with rapid establishment and sustained long-term stability. However, current flow-based gradient chips are often constrained by limited spheroid culture capacity, restricting their utility for large-scale drug evaluation. Here, we developed a microfluidic gradient platform embedded with high-density microwell arrays (MEG platform), which enables high-throughput and physiologically relevant spheroid culture across multiple chambers on a single chip. The total number of spheroids is flexibly tuned by adjusting the microwell array sheet size, and both monoculture and co-culture spheroids maintain continuous and stable growth with well-defined morphology. The platform demonstrates stable gradient delivery under dynamic perfusion. It is further applied to assess drug responses in monoculture and co-culture spheroids, with co-cultures exhibiting enhanced resistance compared with monocultures. The high-throughput MEG platform should facilitate the use of tumor spheroid models in large-scale drug testing and tumor-stromal interaction studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.